Boronated monoclonal antibody conjugates for neutron capture therapy

Monoclonal antibodies (MoAbs) to tumor-associated antigens are attractive for concentrating 10B in cancer tissue, in part because neutron capture therapy (NCT) is not disadvantaged by the hours to days required to optimize tumor:background concentration ratios of MoAbs or their F(ab')2 or Fab fragments. Since direct coupling of 10B compounds in amounts sufficient for radiotherapy appears to inactivate MoAbs, the authors used dextran intermediate carriers to provide high levels of 10B per MoAb while modifying fewer amino acid residues